TABLE 3

Multivariate Model Predicting 3-Day Revisits Among 27 317 Children Aged 7 to 18 Years Receiving Pharmacological Treatment in the ED for Migraine and Discharged From the ED Across 35 Academic Children’s Hospitals, 2009–2012

Most Common Treatment RegimensnUnadjusted 3-d ED Revisit Rate %Adjusted 3-d ED Revisit Rate,a %Adjusted Odds of 3-d ED Revisit (95% CI)a
Nonopioid analgesics27463.84.41.0 (referent)
Nonopioid analgesics, dopamine antagonists, and diphenhydramine33226.86.41.47 (1.21–1.80)
Nonopioid analgesics and dopamine antagonists38665.45.11.17 (0.93–1.47)
Nonopioid analgesics and ondansetron16635.05.31.20 (0.95–1.52)
Dopamine antagonists and diphenhydramine9695.55.31.22 (0.81–1.84)
Dopamine antagonists7755.95.81.34 (0.97–1.86)
Nonopioid analgesics, ondansetron, and diphenhydramine7094.95.01.14 (0.79–1.63)
Dopamine antagonists, nonopioid analgesics, antiepileptics, and diphenhydramine29911.410.12.44 (1.80–3.31)
All other permutations48707.27.21.70 (1.39–2.08)
  • a Adjusted for age, gender, race, insurance status, intravenous fluids, lumbar puncture, cranial computed tomography, cranial magnetic resonance imaging, and SCS score. CI, confidence interval.